✦ LIBER ✦

Variable response of hidradenitis suppurativa to infliximab in four patients

✍ Scribed by N. Usmani; T. H. Clayton; S. Everett; M. D. J. Goodfield

Book ID: 108694221
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 454 KB
Volume: 32
Category: Article
ISSN: 0307-6938
DOI: 10.1111/j.1365-2230.2006.02272.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictors of early response to inflixim

Predictors of early response to infliximab in patients with ulcerative colitis

✍ Marc Ferrante; Séverine Vermeire; Konstantinos H. Katsanos; Maja Noman; Gert Van 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 1 views

## Background: Our objective is to report the outcome of infliximab (ifx) in ulcerative colitis (uc) patients from a single center and to identify predictors of early clinical response. ## Methods: The first 100 uc patients (45 female; median age, 37.9 years) who received ifx at a single center w

Association of the major histocompatibil

Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients

✍ Alfonso Martinez; Marina Salido; Gema Bonilla; Dora Pascual-Salcedo; Miguel Fern 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB 👁 2 views

## Objective: To determine whether major histocompatibility complex (mhc) polymorphisms are associated with a good or poor response to infliximab therapy in patients with rheumatoid arthritis (ra). ## Methods: Seventy-eight infliximab-treated patients with ra were genotyped for hla-drb1, hla-dqa1

Altered dendritic cell function in respo

Altered dendritic cell function in response to sera of common variable immunodeficiency patients

✍ M. Nourizadeh; A. Aghamohammadi; S. M. Moazzeni; M. Mahdavi; A. Jalili; N. Rezae 📂 Article 📅 2007 🏛 SP Birkhäuser Verlag Basel 🌐 English ⚖ 291 KB

Efficacy of mizoribine pulse therapy in

Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab

✍ Masanobu Horikoshi; Satoshi Ito; Mizue Ishikawa; Naoto Umeda; Yuya Kondo; Hiroto 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 293 KB

The efficacy of shortening the dosing in

The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab

✍ U. Kopylov; G. J. Mantzaris; K. H. Katsanos; C. Reenaers; P. Ellul; J. F. Rahier 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

Open-label study of adalimumab in patien

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab

✍ Waqqas Afif; Jonathan A. Leighton; Stephen B. Hanauer; Edward V. Loftus Jr; Will 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Background: The aim of this study was to assess the clinical benefit and tolerability of adalimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF), in patients with ulcerative colitis (UC). Methods: Patients with active UC, including those who had lost response or developed